Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.
Hematol Oncol Stem Cell Ther
; 11(4): 225-232, 2018 Dec.
Article
en En
| MEDLINE
| ID: mdl-29705566
ABSTRACT
BACKGROUND:
High dose Cyclophosphamide (Cy) and Vinorelbine Cyclophosphamide (Vino-Cy) are stem cell (SC) mobilisation options for patients with multiple myeloma (MM). We present a comparison of mobilisation outcomes using these regimens. PATIENTS ANDMETHODS:
Vino-Cy patients received Vinorelbine 25â¯mg/m2 on day 1, cyclophosphamide 1500â¯mg/m2 on day 2, and pegylated GCSF on day 4 or GCSF 10â¯mcg/kg/day from day 4 onwards. Cy patients were given cyclophosphamide 4000â¯mg/m2 on day 1 and GCSF10â¯mcg/kg/day from day 5 onwards. The target CD34â¯+â¯SC collection was 5â¯×â¯106â¯per kg/BW.RESULTS:
149 patients were included. SC collection was lower in the Vino-Cy group (8.20â¯×â¯106/Kg BW) compared to the Cy group (11.43â¯×â¯106/Kg BW), with adjusted geometric mean ratio of 0.59 (95% CI 0.41 to 0.86, pâ¯=â¯0.006). Time taken to achieve an adequate PB SC count was shorter for Vino-Cy (9⯱â¯1â¯day compared to 12⯱â¯2â¯days for Cy, adjusted absolute mean difference -3.95, 95% CI -4.85 to -3.06, Pâ¯<â¯.001). Mobilisation related toxicities (in particular, neutropaenic fever) were greater for Cy.CONCLUSION:
Vino-Cy is a potential alternative to Cy given the need for effective mobilisation protocols with acceptable toxicity.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Movilización de Célula Madre Hematopoyética
/
Ciclofosfamida
/
Células Madre de Sangre Periférica
/
Vinorelbina
/
Mieloma Múltiple
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hematol Oncol Stem Cell Ther
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
Año:
2018
Tipo del documento:
Article